Cellular Origins and Immatics expanded their manufacturing technology collaboration, agreeing to use Cellular Origins’ automated mobile robotic platform, Constellation, for parts of Immatics’ cell therapy manufacturing processes. The partnership is intended to identify how automation can improve efficiency and scalability for next-generation cell therapies. Immatics said the collaboration will support its precision targeting programs focused on PRAME, which it noted is expressed across more than 50 cancers. Management also pointed to the broader industry bottleneck where manual processes limit the number of patients who can access approved therapies, particularly as solid-tumor programs advance. Cellular Origins said automation could help address manufacturing challenges that slow the scale-up of clinically validated approaches. The partnership also places Constellation as a modular platform designed to be deployed in relevant manufacturing workflows, including potential applications to improve throughput and consistency as programs move toward approvals.